Pruritus

SAN DIEGO — Once-daily FXR314 was well-tolerated and safely improved liver fat content and biochemical markers over 16 weeks in patients with metabolic dysfunction-associated steatohepatitis, according to research at The Liver Meeting.

Recent advancements have been made in the treatment of primary biliary cholangitis, particularly for patients who do not respond adequately to first-line treatment.

Chronic kidney disease-associated pruritus may often be insufficiently treated and can disrupt dialysis treatment for patients who report itch to health care providers.

A low dose of interleukin-2 therapy showed positive results in the treatment of bullous pemphigoid with an early onset of response, according to a study.

A topical cream containing cannabis “significantly reduced the severity of itching” symptoms in patients with chronic kidney disease-related pruritus, according to published data.

Nemolizumab doses of 30 mg and 60 mg with topical corticosteroid treatment yielded positive results in adolescent patients with prurigo nodularis, according to a study.

Rapid itch reduction was positively correlated with treatment response among patients taking dupilumab for bullous pemphigoid, according to a study.

The FDA approved the novel immunotherapy denileukin diftitox-cxdl for treatment of certain patients with relapsed or refractory cutaneous T-cell lymphoma.

Cendakimab was effective and generally safe in the treatment of moderate to severe atopic dermatitis in adults, according to a press release.

Clinicians should consider dupilumab as a therapeutic option for bullous pemphigoid due to its ability to clear blistering and pruritus safely, according to a study.